Literature DB >> 24575170

Pattern of failure after high-dose thoracic radiation for non-small cell lung cancer: the University of Michigan experience.

Klaudia U Hunter1, Feng-Ming Spring Kong1, Indrin J Chetty1, Paul Cronin2, Daniel Tatro1, Charles Marn2, James A Hayman1, Randall K Ten Haken1.   

Abstract

PURPOSE: Our main purpose is to study the pattern of local failure for patients with non-small cell lung cancer treated with conformal therapy.
METHODS: This study included patients who failed locally and a matched group without failures after 3D conformal radiation per a radiation dose-escalation trial. Radiation doses ranged from 65.1 to 102.9 Gy in 2.1 Gy fractions, originally computed using an equivalent path length algorithm. The recurrent gross target volumes (RGTV) were contoured. The original and recurrent planning target volume (PTV and RPTV) were generated by 1 cm uniform expansion from GTV. DVHs and generalized equivalent uniform doses (EUD={Σ i (di ) a }1/a ) were computed. Marginal failures were defined for RGTVs covered by the original 10 to 90 % isodose surfaces.
RESULTS: There were no significant differences between the failed and control groups with regard to average original GTV volumes, GTV and PTV doses, and minimum PTV doses. Of the 18 RGTVs, four had marginal failure, 12 failed mostly within, and two failed outside of the original PTV. The mean EUDs were 57.1 Gy (95 % confidence interval (CI) 43.9-70.6) and 47.5 Gy (95 % CI 33.7-61.2), for the RGTVs and RPTVs, respectively, significantly below the prescribed doses (p=0.03). EUDs were less than 60 Gy for 39 % of the RGTVs and 56 % of the RPTVs.
CONCLUSIONS: Recurrent tumors had significantly lower doses than the prescribed dose suggesting that some of these failures could have been avoided with modern technology such as 4D CT simulation and image-guided radiation therapy.

Entities:  

Keywords:  3D conformal radiation; Non-small cell lung cancer; Pattern of local failure

Year:  2012        PMID: 24575170      PMCID: PMC3933260          DOI: 10.1007/s13566-012-0021-3

Source DB:  PubMed          Journal:  J Radiat Oncol        ISSN: 1948-7908


  13 in total

1.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial.

Authors:  J A Hayman; M K Martel; R K Ten Haken; D P Normolle; R F Todd; J F Littles; M A Sullivan; P W Possert; A T Turrisi; A S Lichter
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

2.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

3.  Intra-thoracic failure pattern and survival status following 3D conformal radiotherapy for non-small cell lung cancer: a preliminary report.

Authors:  C R Chien; S W Chen; C Y Hsieh; J A Liang; S N Yang; C Y Huang; F J Lin
Journal:  Jpn J Clin Oncol       Date:  2001-02       Impact factor: 3.019

4.  High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer.

Authors:  J M Watkins; A E Wahlquist; A J Zauls; E C Fields; E Garrett-Mayer; E G Aguero; G A Silvestri; A K Sharma
Journal:  J Med Imaging Radiat Oncol       Date:  2010-12       Impact factor: 1.735

5.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.

Authors:  Mitchell Machtay; Kyounghwa Bae; Benjamin Movsas; Rebecca Paulus; Elizabeth M Gore; Ritsuko Komaki; Kathy Albain; William T Sause; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-25       Impact factor: 7.038

6.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.

Authors:  Feng-Ming Kong; Randall K Ten Haken; Matthew J Schipper; Molly A Sullivan; Ming Chen; Carlos Lopez; Gregory P Kalemkerian; James A Hayman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

7.  The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.

Authors:  Li Wang; Candace R Correa; Lujun Zhao; James Hayman; Gregory P Kalemkerian; Susan Lyons; Kemp Cease; Dean Brenner; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-17       Impact factor: 7.038

8.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer.

Authors:  Ramesh Rengan; Kenneth E Rosenzweig; Ennapadam Venkatraman; Lawrence A Koutcher; Jana L Fox; Reena Nayak; Howard Amols; Ellen Yorke; Andrew Jackson; C Clifton Ling; Steven A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

9.  Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer.

Authors:  Samir Narayan; George T Henning; Randall K Ten Haken; Molly A Sullivan; Mary K Martel; James A Hayman
Journal:  Lung Cancer       Date:  2004-04       Impact factor: 5.705

10.  Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Authors:  P Kumar; J Herndon; M Langer; L J Kohman; A D Elias; F C Kass; W L Eaton; S L Seagren; M R Green; D J Sugarbaker
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

View more
  1 in total

1.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Authors:  Feng-Ming Kong; Randall K Ten Haken; Matthew Schipper; Kirk A Frey; James Hayman; Milton Gross; Nithya Ramnath; Khaled A Hassan; Martha Matuszak; Timothy Ritter; Nan Bi; Weili Wang; Mark Orringer; Kemp B Cease; Theodore S Lawrence; Gregory P Kalemkerian
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.